Guggenheim raised the firm’s price target on Regeneron (REGN) to $865 from $815 and keeps a Buy rating on the shares following Q3 performance that was driven by strong Dupixent sales. Upcoming potential catalysts include full data from cemdisiran in generalized myasthenia gravis, the upcoming PDFUAs for Eylea HD label expansions, and LAG-3 data in melanoma in the first half of 2026, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron price target raised to $627 from $543 at BofA
- Cautious Outlook on Regeneron Amid Eylea Erosion and Medicare Policy Risks
- Regeneron Pharmaceuticals Faces Financial Risks Amid Tariff and Trade Challenges
- Regeneron Pharmaceuticals Reports Q3 2025 Financial Results
- Regeneron Earnings Call: Strong Growth Amid Challenges